Concr wins the Most Anticipated Predictive Diagnostics Platform at GHP’s 2022 Biotechnology Awards

01 Apr 2022

Concr has been selected by the Global Health & Pharma’s annual Biotechnology Awards panel as this year’s winner of the Most Anticipated Predictive Diagnostics Platform.

Global Health and Pharma magazine ( is a global information-sharing platform & a multi-disciplinary member’s community. Their Biotechnology Awards programme is designed to recognise and award leading pioneers in biotechnology globally and has been running for seven consecutive years. As a brand, GHP takes pride in awarding businesses and professionals who have gone above and beyond to play a pivotal role within this ever-evolving sector.

At Concr we are delighted to receive this recognition, which is a testament not only to the achievements of our expert team and cutting-edge technology but also to our collaborators, partners and investors, who share our vision and values. The potential of computational modelling in precision medicine is limitless, and we’re excited to help realise this potential.